Infant Bacterial Therapeutics Investor Relations Material
Latest events
Study Update
Infant Bacterial Therapeutics
Q2 2025
20 Aug, 2025
Q1 2025
7 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IBT
Country
🇸🇪 Sweden